1Breilh D, Jougon J, D jabarouti S, et al. Diffusion of oral and intravenous 400 mg once daily moxifloxaein into lung tissue at pharmacokinetic steady state [J]. J Chemother, 200a, 15 ( 6 ) : 558-562.
2Schein J, janagap-Benin C. A comparison of levofloxacin and moxifloxacin use in hospitalised community acquired pneumonia (CAP)patients in the US:focus on length of stay[J]. Curr Med Res Opin,2008,24(3) :895-906.
5Tortes A, Muir JF, Corris P, et al. Effectiveness of oral moxifloxacin in standard first-line therapy in community acquired pneumonia[J]. Rur Respir J, 2003,21(1) : 135-143.
4Fish DN.Levofloxacin: update and perspectives on one of the original “respiratory quinolones” [J] .Exp Revi Antiinflect Ther, 2003,1(3) : 371.
5Marrie TJ ,Experience with levofloxacin in critical pathway for the treatment of community-acquired pneumonia [J ] . ChemotheraDy, 2004,50( Suppl 1) : 11.
6Bartlett JG, Dowell SF, Mandell LA, et al .Practice guidelines for the management of community - acquired pneumonia in adults. Infectious diseases society of america [J ] . Clin Infect Dis, 2000,31(2) : 347.
7Schein J,Janagap-Benin C. A comparison of levofloxacin m~d moxifloxa- cin use in hospitalized community acquired pneumonia( CAP)patients in the US:focus on length of stay[J]. Cu~Med Res Opin,2008,24 (3): 895 -906.
8Tortes A, Muir JF, Con'is P, er al. Effectiveness of or',d moxifloxacin in standard first-line therapy in community acquired pneumonia [ J ]. Rur- Respir J ,2003,21 ( 1 ) : 135 - 143.
